GILD
HEALTHCAREGilead Sciences Inc
$136.30+2.82 (+2.11%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving GILD Today?
No stock-specific AI insight has been generated for GILD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$93.70$156.40
$136.30
Fundamentals
Market Cap$169.2B
P/E Ratio20.1
EPS$6.77
Dividend Yield0.02%
Dividend / Share$3.16
ROE0.4%
Profit Margin0.3%
Debt / Equity—
Trading
Volume6.4M
Avg Volume (10D)—
Shares Outstanding1.24B
GILD News
46 articles- Crossmark Global Holdings Inc. Buys 23,719 Shares of Gilead Sciences, Inc. $GILDMarketBeat·May 9, 2026
- Is It Time To Reassess Amgen (AMGN) After A Steady Share Price And Strong DCF CaseSimply Wall Street·May 9, 2026
- Gilead Slips As Descovy Steals The 'Spotlight' From Big Yeztugo ExpectationsYahoo Finance·May 8, 2026
- Gilead posts positive Q1 buoyed by HIV drug growthPharmaceutical-technology·May 8, 2026
- Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley SaysYahoo Finance·May 8, 2026
- GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS ViewYahoo Finance·May 8, 2026
- Gilead Sciences, Inc. (NASDAQ:GILD) Plans Quarterly Dividend of $0.82MarketBeat·May 8, 2026
- Gilead (GILD) Q1 2026 Earnings Call TranscriptMotley Fool·May 8, 2026
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cutsFierce Pharma·May 8, 2026
- Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost.Yahoo Finance·May 8, 2026
- Gilead Sciences Announces First Quarter Financial ResultsBioSpace·May 8, 2026
- Gilead Sciences Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Gilead slips despite Q1 beats as it now expects 2026 loss per shareMSN·May 7, 2026
- Gilead slips despite Q1 beats as it now expects 2026 loss per shareSeeking Alpha·May 7, 2026
- Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 7, 2026
- Gilead Sciences (GILD) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·May 7, 2026
- Galapagos Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Gilead Sciences Expects Loss This Year on Acquired R&D ExpensesWSJ·May 7, 2026
- Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On RevenueYahoo Finance·May 7, 2026
- Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q1 Adjusted EPS $2.03 per Sharemarketscreener.com·May 7, 2026
- Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent HighlightsYahoo Finance·May 7, 2026
- Equities Fall Intraday, Oil Rises as Traders Monitor Middle East DevelopmentsYahoo Finance·May 7, 2026
- Gilead Sciences shares decline 1.36% ahead of first quarter earningsMint·May 7, 2026
- Gilead wipes out most of Arcellx workforceBioSpace·May 7, 2026
- WealthShield Partners LLC Takes $1.73 Million Position in Gilead Sciences, Inc. $GILDMarketBeat·May 7, 2026
- Lilly, Gilead lead pharma’s M&A boomPharma Voice·May 7, 2026
- Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts AheadBenzinga·May 7, 2026
- Stocks Rise Pre-Bell as Traders Monitor Developments on Potential US-Iran Peace DealYahoo Finance·May 7, 2026
- Indivisible Partners Purchases New Stake in Gilead Sciences, Inc. $GILDMarketBeat·May 7, 2026
- Alecta Tjanstepension Omsesidigt Makes New $99.95 Million Investment in Gilead Sciences, Inc. $GILDMarketBeat·May 7, 2026
- Oncolytics Biotech Reports Data in Colorectal Cancer StudyYahoo Finance·May 6, 2026
- Galapagos Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Why The Dip In TEM Stock Is A Buying WindowTrefis·May 6, 2026
- Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead ShiftYahoo Finance·May 6, 2026
- Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc.·Apr 28, 2026
- Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswire Inc.·Apr 23, 2026
- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsightGlobeNewswire Inc.·Apr 16, 2026
- Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire Inc.·Apr 8, 2026
Price Data
Open$133.38
Previous Close$133.48
Day High$136.75
Day Low$133.19
52 Week High$156.40
52 Week Low$93.70
52-Week Range
$93.70$156.40
$136.30
Fundamentals
Market Cap$169.2B
P/E Ratio20.1
EPS$6.77
Dividend Yield0.02%
Dividend / Share$3.16
ROE0.4%
Profit Margin0.3%
Debt / Equity—
Trading
Volume6.4M
Avg Volume (10D)—
Shares Outstanding1.24B
About Gilead Sciences Inc
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—